Clareo Health | A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acorda Therapeutics
The primary objective is to determine the relative bioavailability of two CVT-301 (dose levels 1 and 2) capsules compared with the Reference Listed Drug (RLD) on a per milligram basis.
Age
25–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
In good general health as determined by medical history, physical examination, electrocardiogram (ECG), vital signs, and clinical laboratory evaluation;
FEV1/FVC above the 5th percentile of the predicted normal distribution for age and gender;
Body Mass Index (BMI) between 18 - 30 kg/m2
You may not be if
No flu-like syndrome or other respiratory infections within 2 weeks prior to the Screening Visit;
